Welcome to our dedicated page for TENAX THERAPEUTICS SEC filings (Ticker: TENX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tenax Therapeutics filings document a Phase 3, development-stage pharmaceutical company developing cardiopulmonary therapies, including TNX-103 (oral levosimendan) for PH-HFpEF. Recent 8-K reports record financial results, clinical program updates for LEVEL and LEVEL-2, intellectual-property notices, and amendments to levosimendan license rights, including expanded worldwide rights for orally administered products.
Proxy and current-report filings also describe Nasdaq-listed common stock, executive appointments, employment and compensation arrangements, equity awards, governance matters, and named-executive pay disclosures. These records frame the company's capital structure, leadership responsibilities, material agreements, and clinical-stage operations around levosimendan development and commercialization rights.
Tenax Therapeutics, Inc. (TENX) received an amended Schedule 13G/A from ING Groep N.V. and ING Capital Markets LLC reporting that, as of September 11, 2026, they no longer beneficially own any shares of Tenax common stock. All reported voting and dispositive powers have been reduced to zero.
The ownership percentages are calculated against 37,423,917 shares of Tenax common stock outstanding as of July 28, 2026, as referenced from Tenax’s Quarterly Report for the period ended June 30, 2026.
Tenax Therapeutics, Inc. (TENX) furnished an investor presentation summarizing full Phase 3 LEVEL trial results for oral levosimendan (TNX-103) in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). Over 12 weeks, levosimendan did not meet the primary endpoint of improving 6-minute walk distance (6MWD) versus placebo, with a least-squares mean treatment difference of 3.5 meters and a p-value of 0.63.
The presentation highlights prespecified and post-hoc subgroup analyses suggesting larger treatment effects in patients with greater baseline functional limitation (baseline 6MWD below 333 meters), including a 26.3-meter placebo-adjusted LS mean improvement in 6MWD with nominal p=0.0112. Across the overall population, NT-proBNP was reduced by about 49% versus placebo and right ventricular systolic pressure declined by 3.5 mmHg. Safety data show similar rates of serious adverse events between arms, with higher treatment-related adverse events, dose reductions and discontinuations on levosimendan, mainly headache, palpitations and hypotension. Tenax states that insights from LEVEL are being used to refine the design and patient selection strategy for a planned LEVEL-2 study.
TENAX THERAPEUTICS, INC. (TENX) had a significant shareholder associated with ADAR1 Capital Management, LLC report an open-market purchase of common stock. On September 3, 2026, private investment funds managed by ADAR1 bought 900,000 shares of Tenax common stock at a weighted average price of $1.7824 per share, in multiple trades between $1.78 and $1.80. Following this transaction, entities managed by ADAR1 reported 6,524,151 shares of Tenax common stock held indirectly, with each reporting person disclaiming beneficial ownership beyond any pecuniary interest.
TENAX THERAPEUTICS, INC. (TENX) has a significant shareholder group reported on a Schedule 13G. ADAR1 Capital Management, LLC and its sole manager, Daniel Schneeberger, report beneficial ownership of 5,257,389 shares of common stock, representing 14.0% of Tenax’s common stock outstanding as of July 28, 2026.
The shares are held through private investment funds and separately managed accounts advised by ADAR1, with shared voting and dispositive power and no sole power. ADAR1-related funds and accounts also hold pre-funded warrants for 59,073 shares and warrants for 31,096 shares, which are excluded from the reported ownership due to a 4.99% beneficial ownership limitation on each warrant.
TENAX THERAPEUTICS, INC. (TENX) is the subject of an amended Schedule 13G/A filing in which FMR LLC reports beneficial ownership of its common stock. FMR LLC and Abigail P. Johnson report beneficial ownership of 514,925 shares of TENAX common stock, representing 1.4% of the class.
FMR LLC reports sole voting power over 514,450 shares and sole dispositive power over 514,925 shares, with no shared voting or dispositive power. The filing states that one or more other persons may have rights to receive dividends or sale proceeds for these shares, but no such person holds more than five percent of the outstanding common stock.
For TENAX THERAPEUTICS, INC. (TENX), private investment funds managed by ADAR1 Capital Management, LLC, which may be deemed ten percent owners along with Daniel Schneeberger, reported open‑market purchases of a total of 770,333 shares of common stock over August 31 to September 2, 2026. The purchases were made indirectly through these funds at weighted average prices around $1.79 per share, with individual trades ranging from $1.77 to $1.80 per share as disclosed. The reporting persons state that the securities are owned directly by the ADAR1-managed funds and that each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest, and no Rule 10b5‑1 trading plan is reported.
TENAX THERAPEUTICS, INC. (symbol ING) is reported to have a significant shareholder position held through ING Groep N.V. and its wholly owned subsidiary ING Capital Markets LLC. These reporting persons disclose beneficial ownership of 2,639,666 shares of Tenax common stock, with shared voting and dispositive power over all of these shares and no sole power.
This position represents approximately 7.05% of Tenax’s common stock, based on 37,423,917 shares outstanding as of July 28, 2026, as referenced from Tenax’s Form 10‑Q for the quarter ended June 30, 2026. The filing is made on a Schedule 13G, indicating a passive beneficial ownership disclosure rather than an activist intent.
TENAX THERAPEUTICS, INC. (TENX) is reported to have a new significant shareholder group. Investment entities associated with Sphera Funds Management Ltd., including Sphera Global Healthcare GP Ltd. and Sphera Global Healthcare Management LP, report beneficial ownership of 1,993,496 shares of Tenax common stock, representing 5.33% of the class. The ownership percentage is calculated based on 37,423,917 shares outstanding as of July 28, 2026, as reported by Tenax. The filing states that shares are held through Sphera Global Healthcare Master Fund and Sphera Biotech Master Fund, and the Sphera entities expressly disclaim being part of a group or admitting beneficial ownership beyond what is legally required.
TENAX THERAPEUTICS, INC. (TENX) reported insider activity by ADAR1 Capital Management, LLC and Daniel Schneeberger, each a ten percent owner. Private investment funds managed by ADAR1 purchased a total of 1,025,867 shares of TENX common stock indirectly on August 20, 21 and 24, 2026 at weighted average prices around $1.75–$1.78 per share in multiple open-market transactions. The securities are held by the ADAR1-managed funds and may be deemed indirectly beneficially owned by ADAR1 and Schneeberger, who each disclaim beneficial ownership beyond any pecuniary interest.
TENAX THERAPEUTICS, INC. (TENX) has a new initial ownership report from ADAR1 Capital Management, LLC and Daniel Schneeberger as ten percent owners under Section 16. Private investment funds managed by ADAR1 hold 3,827,951 shares of common stock indirectly, plus derivative securities.
The funds also hold Pre-Funded Warrants exercisable for 59,073 shares of common stock at an exercise price of $0.01 per share, with no expiration, and Warrants exercisable for 31,096 shares at $4.50 per share, exercisable until the earlier of September 22, 2026 or exercise of the Pre-Funded Warrants. Both warrant types include a 4.99% beneficial ownership cap. Each reporting person disclaims beneficial ownership beyond any pecuniary interest.